Bristol-Myers Squibb Co Stock Price, News & Analysis

Bristol Myers Squibb (NYSE: BMY) will report results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results on a conference call beginning at 8:00 a.m. ET, with a live webcast available to investors and the public at http://investor.bms.com. Presentation materials will be posted to the same site before the call.

A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. Contact emails: media@bms.com and investor.relations@bms.com.

Bristol Myers Squibb (NYSE: BMY) announced on December 11, 2025 that the U.S. FDA has accepted and granted priority review to the supplemental BLA for Opdivo (nivolumab) plus AVD for previously untreated Stage III or IV classical Hodgkin lymphoma in adults and pediatric patients 12 years and older. The FDA assigned a PDUFA target action date of April 8, 2026. The filing is supported by the randomized Phase 3 SWOG S1826 (CA2098UT) study, which lists progression-free survival as the primary endpoint and overall survival among key secondary endpoints. The study is sponsored by the National Cancer Institute and co-sponsored and supplied by Bristol Myers Squibb.

Bristol Myers Squibb (NYSE: BMY) announced a quarterly common-stock dividend of $0.63 per share, payable on February 2, 2026 to holders of record as of January 2, 2026. This quarterly rate is a 1.6% increase from last year’s $0.62 rate and implies an annual dividend rate of $2.52 for fiscal 2026 (subject to the board’s quarterly review). The company also declared a quarterly dividend of $0.50 per share on its $2.00 convertible preferred stock, payable March 2, 2026 to holders of record as of February 3, 2026. This marks the 17th consecutive year the company has increased the dividend and the 94th consecutive year the company has paid a dividend.

Bristol Myers Squibb (NYSE: BMY) presented lymphoma data at ASH 2025 highlighting targeted protein degradation and cell therapy advances. Key readouts: golcadomide plus R-CHOP showed a 24-month PFS of 79% with CMR 88% and MRD negativity 90%; golcadomide plus rituximab in FL showed ORR 97% and CRR 78%; BMS-986458 monotherapy showed ORR 65% overall. Long-term Breyanzi results: four-year PFS 52.2% and OS 61.5% in TRANSFORM; TRANSCEND FL 36-month CR 94% and DOR 70%. No new safety signals reported for investigational agents; Breyanzi safety profile reaffirmed.

Bristol Myers Squibb (NYSE: BMY) announced FDA approval of Breyanzi (lisocabtagene maraleucel) on December 5, 2025, as the first and only CAR T therapy for adults with relapsed or refractory marginal zone lymphoma (MZL) after ≥2 prior systemic therapies.

Approval was based on TRANSCEND FL MZL cohort results: ORR 95.5% (n=66), CR 62.1%, median duration of response not reached, and 90.1% of responders in response at 24 months; safety was consistent with prior data.

Terray Therapeutics announced on December 3, 2025 that it achieved a discovery milestone in its multi-target collaboration with Bristol Myers Squibb (NYSE: BMY). The milestone used Terray’s EMMI platform, which integrates generative AI, high-throughput chemical experimentation, and a rapidly expanding 13B+ target-ligand binding database with an automated lab.

The company said EMMI enables rapid, iterative discovery and optimization of novel small molecules for difficult-to-drug targets by combining advanced hardware, AI models, and structure-activity data to accelerate identification of development candidates for areas with significant unmet medical need.

Bristol Myers Squibb (NYSE: BMS) announced on December 3, 2025 that the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease will continue with additional patient enrollment after a blinded review identified site-level irregularities.

The company excluded data from the affected sites before database lock, ran an independent interim efficacy and safety analysis with FDA consultation, and the Data Monitoring Committee recommended resuming enrollment to the original target population. BMS remains blinded to study data and expects ADEPT program readouts, including ADEPT-2, by end of 2026.

Bristol Myers Squibb (NYSE: BMY) disclosed more than 95 data disclosures, including 27 oral presentations, at ASH 2025 highlighting advances across multiple myeloma, lymphomas and myeloid diseases.

Key clinical updates include durable responses with CELMoD agents: iberdomide (maintenance and combos) showing sustained MRD negativity in newly diagnosed multiple myeloma, golcadomide with continued efficacy at 24 months in aggressive B-cell lymphoma and extended follow-up in R/R FL and DLBCL, and a first-in-class BCL6 ligand-directed degrader showing encouraging activity in R/R NHL.

Long-term liso-cel (Breyanzi) data show sustained benefit at 3–4 years in FL and LBCL; full safety profiles, including CRS and neurologic event rates, were reported.

Bristol Myers Squibb (NYSE: BMY) will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025. The company will appear in a fireside chat beginning at 9:00 a.m. ET. Investors and the public can listen live via http://investor.bms.com, and an archived edition will be available after the session.

The company reiterated its mission to discover, develop and deliver innovative medicines. Media and investor contact emails are provided for follow-up.